AR
SUPN icon

Advisory Research’s Supernus Pharmaceuticals SUPN Stock Holding History

Advisory Research’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$920K Buy
19,782
+187
+1% +$8.98K 0.09% 113
2026
Q1 		$1.01M Sell
19,595
-380
-2% -$19.4K 0.12% 111
2025
Q4 		$993K Buy
19,975
+921
+5% +$44.8K 0.12% 107
2025
Q3 		$911K Buy
19,054
+657
+4% +$26.5K 0.12% 112
2025
Q2 		$580K Buy
18,397
+1,175
+7% +$37.7K 0.09% 122
2025
Q1 		$564K Buy
17,222
+43
+0.3% +$1.52K 0.1% 122
2024
Q4 		$621K Buy
17,179
+82
+0.5% +$2.89K 0.1% 126
2024
Q3 		$533K Buy
17,097
+331
+2% +$10.3K 0.09% 132
2024
Q2 		$448K Buy
16,766
+1,069
+7% +$31K 0.08% 139
2024
Q1 		$535K Sell
15,697
-811
-5% -$24.1K 0.11% 128
2023
Q4 		$478K Sell
16,508
-1,030
-6% -$27.3K 0.07% 241
2023
Q3 		$484K Sell
17,538
-554
-3% -$16.9K 0.07% 284
2023
Q2 		$544K Buy
18,092
+713
+4% +$24.9K 0.07% 279
2023
Q1 		$630K Buy
17,379
+217
+1% +$8.34K 0.1% 223
2022
Q4 		$612K Sell
17,162
-9,562
-36% -$332K 0.06% 227
2022
Q3 		$905K Buy
26,724
+93
+0.3% +$3.03K 0.09% 176
2022
Q2 		$770K Buy
26,631
+2,400
+10% +$68.7K 0.08% 184
2022
Q1 		$783K Buy
+24,231
New +$743K 0.06% 210

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Advisory Research's SUPN Position: Q2 2026 in Review

Advisory Research increased its Supernus Pharmaceuticals (SUPN) stake by 0.95% in Q2 2026, buying an estimated $8.98K and bringing the position to 19,782 shares worth $920K. The position accounts for 0.09% of the portfolio, ranked #113.

Advisory Research first reported a position in SUPN in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.01M in Q1 2026. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Advisory Research held 19,782 shares of Supernus Pharmaceuticals worth $920K as of Q2 2026.
  • Advisory Research bought 187 Supernus Pharmaceuticals shares in Q2 2026, an estimated $8.98K.
  • Supernus Pharmaceuticals made up 0.09% of Advisory Research's portfolio in Q2 2026, its #113 holding.
  • Advisory Research first reported a position in Supernus Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Advisory Research's Supernus Pharmaceuticals position peaked at $1.01M in Q1 2026.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Advisory Research's 13F filing for Q2 2026, filed 13 Aug 2026.